Melissa Moore, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,776 of the $25,628 with a category attached, or 81.1%. Axsome Therapeutics, Inc. accounts for 67.8% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $18,540, more than ten times the $126 reported in 2021.
Across 146 payments — averaging $175.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$17K
- Pfizer$5K
- AbbVie$2K
- Ipsen Innovation$515
- Amgen$167
- Lundbeck LLC$143
- plus $481 from 8 others
Across 227 payments — averaging $1145.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$159K
- Ipsen Innovation$82K
- Upsher-smith Laboratories LLC$17K
- Eli Lilly$2K
What the payments were for
- Speaking & faculty fees$20,77681%
- Travel & lodging$1,0044%
- Food & beverage$3,84815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 16 | $17,384 |
| Pfizer | 35 | $5,271 |
| AbbVie(2 entities) | 62 | $1,666 |
| Ipsen Innovation | 4 | $515 |
| Amgen | 3 | $167 |
| Lundbeck LLC | 6 | $143 |
| Teva Pharmaceuticals USA, Inc. | 2 | $142 |
| Lilly USA, LLC | 6 | $118 |
| Biohaven Pharmaceuticals, Inc. | 3 | $65 |
| Tonix Medicines, Inc. | 3 | $58 |
| Impel Pharmaceuticals LLC | 3 | $53 |
| UCB, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,628 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 128 | $195,099 |
| Nurtec OdtRimegepant Sulfate | 135 | $179,170 |
| QuliptaAtogepant | 97 | $128,533 |
| Emgality PenGalcanezumab-Gnlm | 137 | $118,639 |
| Aimovig AutoinjectorErenumab-Aooe | 126 | $102,588 |
| BotoxOnabotulinumtoxina | 38 | $49,436 |
| Emgality SyringeGalcanezumab-Gnlm | 24 | $25,077 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $12,084 |
| Sumatriptan Succinate | 81 | $3,987 |
| Carbamazepine ErCarbamazepine | 23 | $2,732 |
| Tizanidine Hcl | 71 | $2,727 |
| RizatriptanRizatriptan Benzoate | 86 | $1,779 |
| Eletriptan HbrEletriptan Hydrobromide | 13 | $1,417 |
| Memantine Hcl | 43 | $1,332 |
| Cyclobenzaprine Hcl | 88 | $1,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $1,666 | $373,068263 claims |
| PfizerNurtec Odt | $5,271 | $179,170135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.
Other neurology in Tampa
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
- Katherine StandleyTampa$735K
- Susan SteenTampa$341K
- Rossitza ChichkovaTampa$294K
- Brody HenkelTampa$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.